Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering AG U.S. Expansion Plans Call For Sales Of $1.6 Bil. In 2005

Executive Summary

Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.

You may also be interested in...



Immunex Novantrone MS Use Is Likely To Be Second-Line

Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.

Immunex Novantrone MS Use Is Likely To Be Second-Line

Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.

Teva Acquisition Spree Gives Firm A Boost With Analysts

Anticipation of another merger is helping Teva improve its standing with Wall Street analysts.

Related Content

UsernamePublicRestriction

Register

PS035183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel